This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
for
Non Small Cell Lung Cancer,
Location: Boston MA, Austin, TX 78758 TX, San Antonio TX
Sponsor: Zumutor Biologics Inc.
Sex: All
Age: 18+
Code: NCT06451497
Phase1, Recruiting
Video Education With Result Dependent dIsclosure
for
Genetic Testing, Breast Cancer, Ovarian Cancer,
Location: Boston MA
Sponsor: Dana-Farber Cancer Institute
Sex: All
Age: 18+
Code: NCT05225428
Recruiting
Biomarkers of Resiliency In Childhood Cancer Surgery
for
Pediatric Cancer, Neuroblastoma, Sarcoma,
Location: Rochester MN
Sponsor: Mayo Clinic
Sex: All
Age: 3 - 25
Code: NCT06674811
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Stereotactic Magnetic Resonance Guided Radiation Therapy
Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers
for
Bladder Carcinoma, Genitourinary System Neoplasm,
Location: Duarte CA
Sponsor: City of Hope Medical Center
Sex: All
Age: 18+
Code: NCT05519878
Recruiting
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
for
Advanced Esophageal Squamous Cell Carcinoma,
Location: Jacksonville FL
Sponsor: Mayo Clinic
Sex: All
Age: 18+
Code: NCT06265285
Phase2, Recruiting
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 30
Code: NCT04322318
Phase2, Recruiting
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
for
Invasive Ductal Breast Carcinoma,
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center
Sex: All
Age: 18+
Code: NCT05837767
Recruiting
Project: Every Child for Younger Patients With Cancer
for
Adrenal Gland Pheochromocytoma, Carcinoma In Situ,
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 25
Code: NCT02402244
Recruiting
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
for
Metastatic Castration-Resistant Prostate Cancer (mCRPC),
Location: Boston MA, Providence RI, New Haven CT, New York NY,
Sponsor: Regeneron Pharmaceuticals
Sex: All
Age: 18+
Code: NCT03972657
Phase1, Phase2, Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
for
Phase II, Sacituzumab, Tirumotecan,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT07438626
Phase2, Recruiting
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
for
Small Cell Carcinoma of the Bladder,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT06161532
Phase2, Recruiting
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
for
Adrenal Gland Neoplasm, Hypertension, Bone Diseases, Metabolic,
Location: Bethesda MD
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sex: All
Age: 7 - 70
Code: NCT03374215
Recruiting
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
for
Neuroendocrine Carcinomas, Neuroendocrine Tumors,
Location: Bethesda MD
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18 - 70+
Code: NCT06041516
Phase1, Recruiting
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors